Researchers found that TNBC cells release ICAM1-enriched small EVs and the binding of ICAM1 to its receptor is necessary for the suppressive effect on CD8 + T cell activity, creating an immunosuppressive TME that may contribute to TNBC tumor growth and bone metastasis. The gene discussed is CD8A; the disease is neoplasm.